Ethicon Acquires TachoSil Surgical Patch From Takeda For $400M
Executive Summary
Ethicon will acquire the assets and licenses of TachoSil for $400m and add about 80 Takeda employees, while Takeda will maintain ownership of the TachoSil manufacturing facility in Linz, Austria.
You may also be interested in...
Pacts In Medtech: Cook Will Sell Ambu’s Duodenoscopes; QXMedical Gets UMinnesota’s Bioresorbable Embolic
Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, R&D partnerships and commercial collaborations. This edition covers industry pacts that were signed in May and June 2019.
Takeda Offloads Xiidra As Expected, For $3.4bn Upfront To Novartis
As widely anticipated, Takeda has reached an agreement to divest an ex-Shire ophthalmology drug, as it streamlines the combined post-acquisition business to focus on core therapeutic pillars.
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.